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CURRENT CONCEPTS 
Heterologous Antilymphocyte Globulin* 
THOMAS E. STARZL. PH.D .• M.D. 
T HE immunosuppressive properties of heterolo-gous antilymphocyte serum and its globulin 
derivative have been well known since 1961, when 
it was reported that a variety of immunologic re-
sponses could be weakened in guinea pigs by the 
administration of the antilymphocyte serum or its 
globulin derivative that had been raised in rabbits.1 
These included the marked suppression of delayed 
cutaneous hypersensitivity, a lesser effect on humo-
ral-antibody formation and a relatively feeble miti-
gation of skin homograft.r.ejection. Soon afterward, it 
was unequivocally demonstratedZ.5 that rabbit anti-
lymphocyte serum had remarkable ability to prolong 
the viability of mouse or rat skin grafts even when 
they were transplanted across difficult histocompati-
bility barriers. Moreover, such an effect could of-
ten be obtained with less b.,ert tOlfricity than with 
any previously known immunosuppressive agent. 
As a c.opsequence of these results, there was 
immediate interest in the possible clinical use of 
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antilymphocyte globulin after human organ trans-
plantation or for the treatment of various other 
immunologically directed pathologic state,s. It now 
seems clear that the globulin can be administered to 
man with both benefit and reiative safety in spite of 
certain gaps in knowledge, which are alluded to 
below, but only under carefully controlled circum-
stances. C:D~ , ) ~ 
PREPARATION AND STANDARDIZATION 
Some of the problems derive from the facts that 
tl1ere are neither standard routines for raising anti-
lymphocyte serum nor fully accepted indirect meth-
ods for assaying the potency of the resulting prod-
uct. Virtually all the aforementioned research on 
transplantation in rodents was done with antilym-
phocyte serum raised in rabbits. The lymphocytes 
obtained from the lymph nodes, thymuses or 
thoracic-duct lymph of the species to be immunized 
against were injected intravenously, subcutaneously 
or intradermally into the rabbits with or without 
Freund's adjuvant. The strength of individual batch-
es of antiserum was usually assessed l:w test ~kin 
grafting. Little or no attention was paid to the levels 
of leukoagglutinins or Iymphocytotoxins that the 
_ antilymphocyte serum contained, and when stated 
the titers of the antiwhite-cell antibodies were in-
variably low. For therapy, the serum was given 
intraperitoneally in volumes that, if extrapolated on' 
a weight basis to adult human beings, would be 1 
to 2 liters per individual dose. 
Much of the work subsequently carried out in 
dogs. was designed to surmount these practical dif-
ficulties. In our laboratories, the horse was selected 
as the heterologous serum source partly because of 
its large size and blood volume. Intensive subcuta-
neous immunization with spleen Qr lymph-node 
lymphocytes resulted in very high titers of antidog 
leukoagglutinins and Iymphocytotoxins. When given 
subcutaneously in quantities that wer~ only a frac-
tion of those required for a comparable effect with 
low-titer antiserums, the resulting antilymphocyte 
serum or its globulin derivative prepared by am-
monium sulfate precipitation of the horse serum, 
afforded protection to both canine kidney and liver 
homografts. 
Nevertheless, the value of measuring antiwhite-
cell antibodies to estimate the strength of antilym-
phocyte serum or its globulin derivative has been 
questioned by a number of authorities. In several 
laboratories, some high-titer antiserums have appar-
ently had poor immunosuppressive qualities. The 
converse is not known to have been true in con-
trolled animal experiments. At a symposium held at 
Davos, Switzerland, on March 25-2R. 1968, Monaco, 
Woodruff and Lance, from the Harvard, Edinburgh 
and Mill Hill laboratories respectively, noted that 
their potent antiserums characteristically had high-
grade lymphocytotoxicity. A potentially valuable 
method of directly relating antibody titers to the 
anti rejection properties of antihuman-lymphocyte 
globulin is contained in a stu dye of the ability of 
such a globulin to prevent rejection of skin homo-
grafts in subhuman primates. 
Antilymphocyte giobulin for administration to 
human beings is not yet commercially available and 
has been locally produced only in centers using it 
clinically. In our own institution, cadaveric spleens 
are used as the source of lymphoid tissue, chiefly 
because of the ease of obtaining large enough quan-
tities of antigen for equine immunization. At the 
same time, another horse is given comparable sub-
cutaneous injections of dog-spleen lymphocytes. 
The antilymphocyte globulin is made from the 
blood of both horses in exactly the same way. The 
raw serum can invariably be shown with the appro-
priate serologic examination to require absorption 
with the red cells, platelets and plasma of the spe-
cies against which immunization was conducted, to 
remove extraneous antibodies that can cause pro-
found hemolysis, thrombocytopenia or other toxic 
manifestations. The globulin is then separated ei-
ther by multiple ammonium sulfate precipitation or 
by a DEAE batch technic. The effectiveness of the 
antidog globulin is checked after canine renal 
homotransplantation before the companion human 
product is accepted. It is scarcely necessary to point 
out the deficiencies or possibly even the irrelevancy 
of the parallel immunization technic with two dif-
ferent donor species as a' means of standardization. 
It has been suggested that the quality of such 
antihuman globulin could be greatly improved by 
adjustments in the timing and route of immuniza-
tion, by use of lymphocytes collected from the pe: 
ripheral blood, lymph nodes, the thymus or the 
thoracic duct or by use of the cell membranes of the 
ruptured,lymphocytes. The superiority of the anti-
lymphocyte globulin with any of these deviations 
has yet to be established. . 
GUIDELINES OF THERAPY 
Except for important experiments conducted with 
skin grafts in healthy volunteers7 antilymphocyte 
globulin has not been used as the sole immunosup-
pressive agent after tissue and organ transplantation 
in human beings. There are gool reasons for this. 
The first is that antilymphocyte globulin does not 
always prevent rejection in· inbred-mouse test ~ys­
tems involving skin homografts. Its effects are even 
less predictable in a given experiment after whole-
organ transplantation between unrelated mongrel 
dogs. f~ ~he 'lreported canine studies a minority of 
the recipients of vital organs lived for many months, 
about half had delay but not prevention of rejection, 
and a few rejected their kidneys or livers at the 
same time as would be expected In unmodified 
animals. The same kind of spectrum has been seen 
in the testing of other potent immunosuppressive 
agents such as azathioprine. Presumably, such vari-
ability is due to chance differences in the quality of 
donor-recipient histocompatibility. Fortunately, anti-
lymphocyte globulin has a synergistic action with 
adrenocortical steroids and several chemotherapeu-
tic drugs including azathioprine. 
A secona consideration is the serious toxicity that 
can result from repeated foreign protein injections. 
Since antilymphocyte globulin is an immunosup-
pressant, it could be expected to r~y£eI ~ host 
response to its own alien antigens. To 'some extent, 
this "self-antidotal" effect occurs, but it is not com-
plete. Within a few weeks after institution of 
therapy in animals, immune elimination of the in-
jected heterologous protein develops. Moreover, 
antibodies against the heterologous globulin can be 
demonstrated to develop by other kinds of immuno-
logic tests. Serum-sickness nephritis or anaphylactic' 
reactions have complicated the course of dogs being 
treated with either antilymphocyte serum or its 
globulin derivative, particularly after long-term 
therapy. 
For both the foregoing reasons antilymphocyte 
globulin has been administered intramuscularly to 
our patients as an adjuvant immunosuppressive, 
agent, and its use limited to the first four months ( 
after kidney or liver transplantation.' In the usual 
case the globulin was started three to five days be-
fore _ operation, continued- daily for approximately 
two and a half weeks and then given every other 
day for two weeks, twice a week for two months 
and once a week for a final month. The individual 
doses were 1 to 5 ml, depending on the weight of 
the patient and the antiwhite-cell titer and protein 
content of the antilymphocyte globulin. Reduced 
doses of azathioprine and prednisone were also 
given, starting on the day of operation, and then 
continued after the course of antilymphocyte globu-
lin had been terminated. The immunosuppression 
obtained from the combination of agents was ex-
pected not only to provide better control of rejec-
tion but also to decrease the danger from 'the injec-
tions of horse globulin. 
There is no reason whatever to believe that the 
described schedule of therapy with this agent can-
not be improved. For example, it has been suggested7 
that an appropriate way to give globulin therapy 
would be in "blitzkrieg" fashion, using very much 
larger doses but for a short period. The objective 
would be to deplete the long lived lymphocyte 
population thoroughly and acutely. This approach 
might result in a much more profound (and proba-
bly protracted) immunosuppressive effect, and it 
should reduce the chronic morbidity described be-
low. 
EFFEcr5 OF THERAPY IN MAN 
Adjuvant thempy with the four-month course of 
antilymphocyte globulin has been given to 86 pa-
tients who received renal or hepatic homografts at 
our institutions during the last 22 months; there has 
not been a drug-related mortality with more than 
5000 injections. Before operation many of these 
recipients had positive skin tests to tuberculin, his-
toplasmin or other allergens. These became nega-
tive on retesting 48 to 72 hours after the institution 
of globulin therapy, indicating that the al.!ent pre-
vented expression of a previously established de-
layed hypersensitivity. 
The evidence that antilymphocyte globulin was of 
value after clinical renal transplantation has been 
documented elsewhere.' In brief, mortality and 
homograft loss after intrafamilial homotransplan-
tations were reduced to 5 per cent in the first year, 
the ultimate kidney function was superior to that in 
comparable past cases, and the quantities of aza-
thioprine and prednisone necessary to achieve these 
results were reduced. 
These advantages were not without corresponding 
penaities. IO All of the patients had pain, which was 
often severe, at the site of the injections. Many had 
fever, urticaria, periorbital edema or skin rashes. In 
15 per cent of -the cases therapy had to be discon-
tinued prematurely because of anaphylactic reac-
tions. There was a rough correlation between the 
development of the anaphylactic reactions and the 
appearance in their serum of agglutinins against 
sheep red blood cells and antihorse-protein precip-
itins. The former probably measure the response to 
Forssman antigen in the equine protein. The latter 
antibodies were principally directed against the 
variable quantities of alpha and beta globulins that 
were in the antilymphocyte globulin produced by 
niultiple ammonium sulfate precipitation. For the 
last several months, a pure gamma-G globulin pre- _ 
pared with· a DEAE-cellulose- batch technic has 
been used in patients. Rises in precipitin titers have 
not been seen, but elevations in hemagglutinin lev-
els h;ave been of the same magnitude as with the 
less refined ~ntilymphocyte globulin originally used. 
Anaphylactic reactions have not yet occurred. How-
ever, the protection to the whole-organ homografts 
seem to have been considerably less than with the 
crude ALG originally used. 
At the moment, it does not seem that the threat of 
either serum sickness or Masugi (direct nephrotoxic) 
nephritis will be a major deterrent to the clinical 
use of antilymphocyte globulin, at least in the con-
text of the combination therapy that has already 
been tested. Eleven of 12 renal-homograft biopsies. 
. -t. 
obtained from patients treated with this agent have -
not had horse protein detectable with immunoflu-
orescence technics. 
K.( I~ PROSPEcr5 
Even now, it seems probable that heterologous 
antilymphocyte globulin will become a widely used 
immunosuppressive drug. With the clarification of 
standards for raising the antiserum and measuring 
its potency, many of the cumbersome control proce-
dures and precautions mentioned earlier will no 
longer be necessary. Conceivably, the determination 
of the optimum heterologous serum donor, the use 
of subcellular fragments as antigen and the applica-
tion of technics for removal of only the desired im-
munoglobulin fractions could eliminate much of 
til(' risk ana morbidity from the hH'etgn-protem in-
jections. As mentioned earlier, it would be surpris-
ing if better programs of administration were not 
devised. Under these circumstancys) tqtiJXJI1phocyte 
globulin might eventually be used as the primary 
rather than as an adjuvant agent in clinical immu-
nosuppressive regimens. At the present state of 
d~velopmentI however, it must still be considered a 
drug that is undergoing experimental evaluation. 
REFERENCES 
I. Waksman. B. H .• Arbouys. S .• and Amason. B. G. Use of 
specific "lymphocyte" antisera to inhibit hypersensitive reactions 
of "delayed" type. J. Exper. Med. 114:997-1022. 1961. 
2. Woodruff. M. F. A .• and Anderson. N. A. Effect of lymphocyte 
depletion by thoracic duct fistula and administration of anti-
lymphocyte serum on survival of skin homografts in rats. Nature 
(London) 200:702. 1963. 
3. Gray. J. G .• Monaco. A. P .• and Russell. P. S. Heterologous 
mouse antilymphocyte serum to prolong skin homografts. Surg. 
Forum 15:142-144. 1964. 
4. Jeejeebhoy. H. F. Immunological studies on rat thymectomize!! in 
adult life. Immunology 9:417-425. 1965. ' 
5. Levey. R. H .• and Medawar. P. B. Some experiments on action 
of antilymphoid antisera. Ann. New York Acad. Sc. 129:164-177. 
1966. 
- 6. BaIner. H .• Eysvoogel. V. P .• and Cleton. F. J. Testing of anti-
- human lymphocyte sera in chimpanzees and lower primates. 
Lancet 1: 19-22. 1968. 
7. Monaco. A. P .• Wood. M. L. and Russell. P. S. Some effects of 
purified heterologous antihuman lymphocyte serum in man. 
Transplantation 5:1106-1114. 1967. 
8. Starzl. T. E .• Porter. K. A .• Iwasaki. Y .• Marchioro. T. L. and 
Kashiwagi. N. Use of antilymphocyte globulin in human renal 
homotransplantation. In Stud\' Group on Alllilympho('yti(' Serum. 
Edited b)' G. E. W. Wolstenholme and M. O'Connor. London: 
Churchill. 1967. Pp. 4-34. 
9. Starzl. T. E .. et al. Heterologous antilymphocyte globulin. histo-
compatibility matching. and human renal homotransplantation. 
Surg .. Gynec. & Ob.tt. 126: 1023-1035. 1968. 
10. Kashiwagi. N .. Brantigan. C. 0 .• Brettschneider. L. Groth. C. G .• 
and Starzl. T. E. Clinical reactions and serologic changes after 
administration of heterologous antilymphocyte globulin to human 
reCipients of renal homografts. Ann. Int. Med. 6,8:275-286. 1968. 
Copyright, 1968. hy the Massachusetts :'Ifedical Society 
Printed in the U. S. A. 
1. 
----,,------------------------4:-
